NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

"SELECT-SWITCH is the first head-to-head trial comparing TNF inhibitor cycling with switching to the JAK inhibitor upadacitinib," said lead study investigator Eduardo Mysler, M.D., rheumatologist and ...

Researchers conducted a multicenter retrospective study involving 92 patients with methotrexate‑induced osteopathy to characterize the affected population, describe fracture patterns, and identify ...

Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Humira is given as an injection, while Remicade is given as an infusion. Humira and ...

Disease-modifying drug therapies are being sought intensively for osteoarthritis (OA), but none have proved out thus far. A previous trial in patients with OA of the hand had found that methotrexate ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Methotrexate is a generic drug prescribed to treat certain types of cancers, arthritis, and psoriasis in adults and some children. As with other drugs, methotrexate can cause side effects, such as ...

Methotrexate (MTX) is a commonly used treatment option for managing refractory atopic dermatitis, especially as an alternative to cyclosporine, anti-interleukins, or anti-JAK treatments. According to ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...